glp 1 cardiac protection Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs How GLP-1 Medications Reduce Heart

The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications

This pillar page explains how medications like Ozempic, Wegovy, and Mounjaro work, how to manage common side effects, and how to structure your diet to protect muscle, maintain energy, and achieve sustainable weight loss results

Cardiovascular-Kidney-Metabolic (CKM) Syndrome , as defined by the AHA, is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors (such as obesity, insulin resistance, dyslipidemia, and hypertension), chronic kidney disease (CKD), and the cardiovascular system, leading to multiorgan dysfunction and a high rate of adverse cardiovascular outcomes [145]

Skin & Connective Tissue Stimulates collagen synthesis and connective tissue repair